News | October 31, 2025
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Subscribe To Our Newsletter & Stay Updated
